Oseltamivir phosphate is indicated for the treatment of influenza A, influenza B, and Others. It reduces the symptoms caused by influenza virus such as stuffy nose, cough, sore throat, fever/chills, aches, and tiredness. Moreover, the medicine reduces the recovery time by 1-2 days. This medication may also be used to prevent the flu if the person is exposed to other patient who already is suffering from flu or if there is a flu pandemic in the community. The mode of action for the treatment is that, this medication works by stopping the flu virus from growing. The medicine should be taken at the proper time interval as prescribed by the doctor. If the intake of medicine is terminated at an early stage then, this may lead to the growth of the virus, which may relapse of the infection.

Market Dynamics

Increasing incidence of influenza among the U.S. population is expected to increase the growth of the global Tamiflu (oseltamivir phosphate) market over the forecast period. For instance, according to the article published in the Lancet journal, 2022, the annual incidence of symptomatic influenza is estimated to vary from 3 to 11%. According to the various studies carried out by the researchers in National Center for Immunization and Respiratory Diseases, U.S., it was found that, influenza virus infections and illness rates are highest in children and the rate of illness decrease with the increasing age.

Increasing launches of Tamiflu (oseltamivir phosphate) is expected to drive the growth of the global Tamiflu (oseltamivir phosphate) over the forecast period. For instance, in 2018, Natco Pharma, Indian pharmaceutical company and their marketing partner Alvogen, U.S. based pharmaceutical company launched, the first generic version of Tamiflu (oseltamivir phosphate) in the U.S.

Key features of the study:

• This report provides in-depth analysis of the global Tamiflu (oseltamivir phosphate) market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Tamiflu (oseltamivir phosphate) market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include F.Hoffmann-La Roche Ltd., NATCO Pharma Limited, Tea Pharmaceutical Industries Ltd., LUPIN Limited, Amneal Pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Mylan N.V., and Hetero Group.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Tamiflu (oseltamivir phosphate) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Tamiflu (oseltamivir phosphate) market

Detailed Segmentation:

• Global Tamiflu (Oseltamivir Phosphate)  Market, By Drug Type:
  • Branded
  • Generic
• Global Tamiflu (Oseltamivir Phosphate) Market, By Dosage Form:
  • Capsules
  • Suspension
• Global Tamiflu (Oseltamivir Phosphate) Market By Indication:
  • Influenza A
  • Influenza B
  • Swine Flu (H1N1 Influenza A)
• Global Tamiflu (Oseltamivir Phosphate) Market By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Tamiflu (Oseltamivir Phosphate) Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • F. Hoffmann-La Roche Ltd.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd.
  • LUPIN Limited
  • Amneal Pharmaceuticals LLC
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • Mylan N.V.
  • Hetero Group

 “*” marked represents similar segmentation in other categories in the respective section.